Production of site-selected neutralizing human monoclonal antibodies against the third variable domain of the human immunodeficiency virus type 1 envelope glycoprotein.

No abstract is available for this paper.

• Publication year

  1991

• Venue

  Proceedings of the National Academy of Sciences of the United States of America

• Publication date

  1991-04-15

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1073/PNAS.88.8.3238PMID 2014246PMCID PMC51421
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Identification of sites within gp41 that serve as targets for antibody-dependent cellular cytotoxicity by using human monoclonal antibodies.

  1990cited by this paper
• Progress in AIDS Pathology

  1990cited by this paper
• Application of a rapid microplaque assay for determination of human immunodeficiency virus neutralizing antibody titers

  1990cited by this paper
• Human monoclonal antibodies to the human immunodeficiency virus type 1 (HIV-1) transmembrane glycoprotein gp41 enhance HIV-1 infection in vitro.

  1990cited by this paper
• Conserved sequence and structural elements in the HIV-1 principal neutralizing determinant.

  1990cited by this paper
• Polymerase chain reaction evidence for human immunodeficiency virus 1 neutralization by passive immunization in patients with AIDS and AIDS-related complex.

  1990cited by this paper
• Neutralization of human immunodeficiency virus type 1 by complement occurs by viral lysis

  1990cited by this paper
• A chink in HIV's armour?

  1990cited by this paper
• Antibody-mediated in vitro neutralization of human immunodeficiency virus type 1 abolishes infectivity for chimpanzees

  1990cited by this paper
• Human monoclonal antibody that recognizes the V3 region of human immunodeficiency virus gp120 and neutralizes the human T-lymphotropic virus type IIIMN strain.

  1990cited by this paper
• Identification of Conserved and Variant Epitopes of Human Immunodeficiency Virus Type 1 (HIV-1) gp120 by Human Monoclonal Antibodies Produced by EBV-Transformed Cell Lines

  1990cited by this paper
• Vertical transmission of human immunodeficiency virus is correlated with the absence of high-affinity/avidity maternal antibodies to the gp120 principal neutralizing domain.

  1990cited by this paper
• Generation and characterization of monoclonal antibodies to the putative CD4-binding domain of human immunodeficiency virus type 1 gp120

  1989cited by this paper
• The Fc and not CD4 receptor mediates antibody enhancement of HIV infection in human cells.

  1989cited by this paper
• Human immunodeficiency virus type 1-neutralizing monoclonal antibodies which react with p17 core protein: characterization and epitope mapping

  1989cited by this paper
• Mother-to-infant transmission of human immunodeficiency virus type 1: association with prematurity or low anti-gp120.

  1989cited by this paper
• Human monoclonal antibodies against a recombinant HIV envelope antigen produced by primary in vitro immunization. Characterization and epitope mapping.

  1989cited by this paper
• Enhancement of Human Immunodeficiency Virus (HIV) Replication in Human Monocytes by Low Titres of Anti‐HIV Antibodies in Vitro

  1989cited by this paper
• Presence of maternal antibodies to human immunodeficiency virus 1 envelope glycoprotein gp120 epitopes correlates with the uninfected status of children born to seropositive mothers.

  1989cited by this paper
• Human immunodeficiency virus-infected T cells and monocytes are killed by monoclonal human anti-gp41 antibodies coupled to ricin A chain.

  1989cited by this paper
• Generation of human monoclonal antibodies to human immunodeficiency virus.

  1989cited by this paper
• Quantitative assay of a human monoclonal IgM antibody (HA-1A) in human serum.

  1989cited by this paper
• Human Monoclonal Antibody Against a gag-Coded Protein of Human Immunodeficiency Virus Produced by a Stable EBV-Transformed Cell Clone

  1989cited by this paper
• Principal neutralizing domain of the human immunodeficiency virus type 1 envelope protein.

  1989cited by this paper
• Human retroviruses and AIDS.

  1988cited by this paper
• Monoclonal antibodies to HIV in a non-infected, immunised volunteer.

  1988cited by this paper
• Human monoclonal antibody directed against gag gene products of the human immunodeficiency virus.

  1988cited by this paper
• A sensitive radioimmunoprecipitation assay for human immunodeficiency virus (HIV).

  1988cited by this paper
• Remission induction in non-Hodgkin lymphoma with reshaped human monoclonal antibody CAMPATH-1H.

  1988cited by this paper
• Generation of a neutralization-resistant variant of HIV-1 is due to selection for a point mutation in the envelope gene.

  1988cited by this paper
• Antibodies that inhibit fusion of human immunodeficiency virus-infected cells bind a 24-amino acid sequence of the viral envelope, gp120.

  1988cited by this paper
• Effects of anti-gp120 monoclonal antibodies on CD4 receptor binding by the env protein of human immunodeficiency virus type 1

  1988cited by this paper
• The high efficiency, human B cell immortalizing heteromyeloma CB-F7. Production of human monoclonal antibodies to human immunodeficiency virus.

  1988cited by this paper
• Effects of passive immunization in patients with the acquired immunodeficiency syndrome-related complex and acquired immunodeficiency syndrome.

  1988cited by this paper
• Human antibody response to a strain-specific HIV-1 gp120 epitope associated with cell fusion inhibition.

  1988cited by this paper
• Human monoclonal antibody against glycoproteins of human immunodeficiency virus.

  1988cited by this paper
• Human retroviruses and AIDS.

  1988influential reference
• Neutralization of diverse HIV-1 strains by monoclonal antibodies raised against a gp41 synthetic peptide.

  1988cited by this paper
• Antibody-dependent enhancement of human immunodeficiency virus type 1 infection.

  1988cited by this paper
• Passive immunoneutralization of human immunodeficiency virus in patients with advanced AIDS.

  1988cited by this paper
• Second conserved domain of gp120 is important for HIV infectivity and antibody neutralization.

  1988cited by this paper
• Neutralizing monoclonal antibodies to the AIDS virus.

  1988cited by this paper
• Characterization and epitope mapping of a human monoclonal antibody reactive with the envelope glycoprotein of human immunodeficiency virus.

  1987cited by this paper
• Human immunodeficiency virus neutralizing antibodies recognize several conserved domains on the envelope glycoproteins

  1987cited by this paper
• Delineation of a region of the human immunodeficiency virus type 1 gp120 glycoprotein critical for interaction with the CD4 receptor.

  1987cited by this paper
• Antigenic analysis of equine infectious anemia virus (EIAV) variants by using monoclonal antibodies: epitopes of glycoprotein gp90 of EIAV stimulate neutralizing antibodies

  1987cited by this paper
• Determination of intrinsic affinity constants of monoclonal antibodies against carcinoembryonic antigen.

  1987cited by this paper
• Computer-assisted analysis of envelope protein sequences of seven human immunodeficiency virus isolates: prediction of antigenic epitopes in conserved and variable regions

  1987cited by this paper
• Neutralization of HTLV-III/LAV replication by antiserum to thymosin alpha 1.

  1986cited by this paper
• Induction of anti‐HIV neutralizing antibodies by synthetic peptides.

  1986cited by this paper
• Immunochemistry of viruses : the basis for serodiagnosis and vaccines

  1985cited by this paper
• Measurements of the true affinity constant in solution of antigen-antibody complexes by enzyme-linked immunosorbent assay.

  1985cited by this paper
• Use of peptide synthesis to probe viral antigens for epitopes to a resolution of a single amino acid.

  1984cited by this paper

• Impact of IgG Isotype on the Induction of Antibody-Dependent Cellular Phagocytosis of HIV by Human Milk Leukocytes

  2021cites this paper
• Distinct conformations of the HIV-1 V3 loop crown are targetable for broad neutralization

  2021cites this paper
• Phage-DMS: A Comprehensive Method for Fine Mapping of Antibody Epitopes

  2020cites this paper
• Kobe University Repository : Kernel タイトル Tit le Molecular Evolut ion of HIV-1 CRF 01 _ AE Env in Thai

  2019cites this paper
• The Envelope-Based Fusion Antigen GP120C14K Forming Hexamer-Like Structures Triggers T Cell and Neutralizing Antibody Responses Against HIV-1

  2019cites this paper
• Phagocytosis of a Model Human Immunodeficiency Virus Target by Human Breast Milk Leukocytes Is Predominantly Granulocyte-Driven When Elicited by Specific Antibody

  2019cites this paper
• Conformational Engineering of HIV-1 Env Based on Mutational Tolerance in the CD4 and PG16 Bound States

  2019cites this paper
• OriginalBasicScienceçGeneral No Evidence for Cross-reactivity of Virus-specific Antibodies With HLA Alloantigens

  2018cites this paper
• No evidence for cross-reactivity of virus-specific antibodies with HLA allo-antigens.

  2018cites this paper
• 66 – Technologies for Making New Vaccines

  2018cites this paper
• Human IgM monoclonal antibodies block HIV-transmission to immune cells in cervico-vaginal tissues and across polarized epithelial cells in vitro

  2018cites this paper
• Primary Human Neutrophils Exhibit a Unique HIV-Directed Antibody-Dependent Phagocytosis Profile

  2018cites this paper
• Optimized protocol for detection of native, full‐length HIV‐1 envelope on the surface of transfected cells

  2018cites this paper
• Evaluation of the fusion partner cell line SPYMEG for obtaining human monoclonal antibodies against influenza B virus

  2018cites this paper
• Reduced Cell-Associated DNA and Improved Viral Control in Macaques following Passive Transfer of a Single Anti-V2 Monoclonal Antibody and Repeated Simian/Human Immunodeficiency Virus Challenges

  2018cites this paper
• Design of HIV Coreceptor Derived Peptides That Inhibit Viral Entry at Submicromolar Concentrations.

  2017cites this paper
• Monoclonal Antibodies Specific for the V2, V3, CD4-Binding Site, and gp41 of HIV-1 Mediate Phagocytosis in a Dose-Dependent Manner

  2017cites this paper
• Comparison of Antibody-Dependent Cell-Mediated Cytotoxicity and Virus Neutralization by HIV-1 Env-Specific Monoclonal Antibodies

  2016cites this paper
• Rationally Targeted Mutations at the V1V2 Domain of the HIV-1 Envelope to Augment Virus Neutralization by Anti-V1V2 Monoclonal Antibodies

  2015cites this paper
• Functional and Structural Characterization of Human V3-Specific Monoclonal Antibody 2424 with Neutralizing Activity against HIV-1 JRFL

  2015cites this paper
• What Do Chaotrope-Based Avidity Assays for Antibodies to HIV-1 Envelope Glycoproteins Measure?

  2015cites this paper
• A broad range of mutations in HIV-1 neutralizing human monoclonal antibodies specific for V2, V3, and the CD4 binding site.

  2015cites this paper
• A Chimeric HIV-1 gp120 Fused with Vaccinia Virus 14K (A27) Protein as an HIV Immunogen

  2015cites this paper
• Development of gold nanoparticle-based antigen delivery platform for vaccines against HIV-1

  2015cites this paper
• Functional Implications of the Binding Mode of a Human Conformation-Dependent V2 Monoclonal Antibody against HIV

  2014cites this paper
• Identification of antibody glycosylation structures that predict monoclonal antibody Fc-effector function

  2014cites this paper
• Differential glycosylation of envelope gp120 is associated with differential recognition of HIV-1 by virus-specific antibodies and cell infection

  2014cites this paper
• A Modern Biopharmaceutical to Treat AIDS – Challenges in Designing HIV Env Immunogens for Developing a Vaccine

  2013cites this paper
• Cross-neutralizing activity of human anti-V3 monoclonal antibodies derived from non-B clade HIV-1 infected individuals.

  2013cites this paper
• 60 – Technologies for making new vaccines

  2013cites this paper
• Développement d'anticorps monoclonaux humains de type IgA dirigés contre la partie C-terminale de la protéine d'enveloppe gp41 du VIH-1

  2013cites this paper
• Pre-Clinical Evaluation of a 213Bi-Labeled 2556 Antibody to HIV-1 gp41 Glycoprotein in HIV-1 Mouse Models as a Reagent for HIV Eradication

  2012cites this paper
• Phages and HIV-1: From Display to Interplay

  2012cites this paper
• Production and characterization of human anti-V3 monoclonal antibodies from the cells of HIV-1 infected Indian donors

  2012cites this paper
• Functional and immunochemical cross-reactivity of V2-specific monoclonal antibodies from HIV-1-infected individuals.

  2012cites this paper
• Role of Human Immunodeficiency Virus Type 1 Envelope Structure in the Induction of Broadly Neutralizing Antibodies

  2012cites this paper
• Assembly and architecture of HIV.

  2012cites this paper
• Ability of antibodies specific to the HIV-1 envelope glycoprotein to block the fusion inhibitor T20 in a cell-cell fusion assay.

  2012cites this paper
• Interaction of the HIV-1 gp120 Viral Protein V3 Loop with Bacterial Lipopolysaccharide

  2011cites this paper
• Human Anti-V3 HIV-1 Monoclonal Antibodies Encoded by the VH5-51/VL Lambda Genes Define a Conserved Antigenic Structure

  2011cites this paper
• Molecular Evolution of HIV-1 CRF01_AE Env in Thai Patients

  2011cites this paper
• HIV-1 Glycoprotein Immunogenicity

  2011cites this paper
• Identification of potential epitopes for the design of HIV-1 vaccine in Kenya

  2011cites this paper
• Designing Immunogens for Vaccine Development in Reference to HIV

  2011cites this paper
• Indirect Detection of an Epitope-Specific Response to HIV-1 gp120 Immunization in Human Subjects

  2011cites this paper
• Polyvalent AIDS vaccines.

  2010cites this paper
• Development of Broadly Reactive HIV-1/AIDS Virus-like Particle Vaccines

  2010cites this paper
• Conserved structural elements in the V3 crown of HIV-1 gp120

  2010cites this paper
• HIV-1 gp120-induced neuroinflammation: relationship to neuron loss and protection by rSV40-delivered antioxidant enzymes.

  2010cites this paper
• Blood-brain barrier abnormalities caused by exposure to HIV-1 gp120--protection by gene delivery of antioxidant enzymes.

  2010cites this paper
• A Rat Model of Human Immunodeficiency Virus 1 Encephalopathy Using Envelope Glycoprotein gp120 Expression Delivered by SV40 Vectors

  2009cites this paper
• Proinflammatory cytokines and HIV‐1 synergistically enhance CXCL10 expression in human astrocytes

  2009cites this paper
• Toward Effective HIV Vaccination

  2009cites this paper
• Preferential use of the VH5-51 gene segment by the human immune response to code for antibodies against the V3 domain of HIV-1.

  2009cites this paper
• Challenges in designing HIV env immunogens for developing a vaccine

  2008cites this paper
• Structure determination of an anti-HIV-1 Fab 447-52D-peptide complex from an epitaxially twinned data set.

  2008cites this paper
• Human Immunodeficiency Virus Type 2 (HIV-2)/HIV-1 Envelope Chimeras Detect High Titers of Broadly Reactive HIV-1 V3-Specific Antibodies in Human Plasma

  2008cites this paper
• Subtype-Specific Conformational Differences within the V3 Region of Subtype B and Subtype C Human Immunodeficiency Virus Type 1 Env Proteins

  2007cites this paper
• Novel approaches for identification of broadly cross-reactive HIV-1 neutralizing human monoclonal antibodies and improvement of their potency.

  2007cites this paper
• HIV-1 Env sequence and structure contribute to both coreceptor tropism and susceptibility to antibody neutralization

  2007cites this paper
• Subtype-Specific Conformational Differences within the V3 Region of Subtype B and Subtype C Human Immunodeficiency Virus Type 1 Env Proteins (cid:1)

  2007cites this paper
• Membrane embedded HIV-1 envelope on the surface of a virus-like particle elicits broader immune responses than soluble envelopes.

  2007cites this paper
• Sequential Immunization with V3 Peptides from Primary Human Immunodeficiency Virus Type 1 Produces Cross-Neutralizing Antibodies against Primary Isolates with a Matching Narrow-Neutralization Sequence Motif

  2006cites this paper
• Cross-Clade Neutralizing Activity of Human Anti-V3 Monoclonal Antibodies Derived from the Cells of Individuals Infected with Non-B Clades of Human Immunodeficiency Virus Type 1

  2006cites this paper
• Selection of a novel gp41-specific HIV-1 neutralizing human antibody by competitive antigen panning.

  2006cites this paper
• Towards irreversible HIV inactivation: stable gp120 binding by nucleophilic antibodies

  2006cites this paper
• Identification of a New Quaternary Neutralizing Epitope on Human Immunodeficiency Virus Type 1 Virus Particles

  2005cites this paper
• A Highly Conserved Arginine in gp120 Governs HIV-1 Binding to Both Syndecans and CCR5 via Sulfated Motifs*

  2005cites this paper
• The HIV-1 V3 domain on field isolates: participation in generation of escape virus in vivo and accessibility to neutralizing antibodies

  2005cites this paper
• Immune complex p24 antigen: A new prognostic marker in human immunodeficiency virus infection

  2005cites this paper
• Infection of human and non-human cells by a highly fusogenic primary CD4-independent HIV-1 isolate with a truncated envelope cytoplasmic tail.

  2005cites this paper
• Role of Neutralizing Antibodies in Protective Immunity Against HIV

  2005cites this paper
• The humoral immune response to HIV-1: Consequences for vaccine design.

  2005cites this paper
• Potency of HIV-1 envelope glycoprotein gp120 antibodies to inhibit the interaction of DC-SIGN with HIV-1 gp120.

  2004cites this paper
• Neutralizing antibody responses to HIV: role in protective immunity and challenges for vaccine design

  2004cites this paper
• The V1/V2 Domain of gp120 Is a Global Regulator of the Sensitivity of Primary Human Immunodeficiency Virus Type 1 Isolates to Neutralization by Antibodies Commonly Induced upon Infection

  2004cites this paper
• Identifying epitopes of HIV-1 that induce protective antibodies

  2004cites this paper
• Requirement of diverse T-helper responses elicited by HIV vaccines: induction of highly targeted humoral and CTL responses

  2004cites this paper
• Defining Human Immunodeficiency Virus (HIV) Type 1 Immunotypes with Six Human Monoclonal Antibodies

  2004cites this paper
• The V3 Loop Is Accessible on the Surface of Most Human Immunodeficiency Virus Type 1 Primary Isolates and Serves as a Neutralization Epitope

  2004cites this paper
• Human Monoclonal Antibodies Specific for Conformation-Sensitive Epitopes of V3 Neutralize Human Immunodeficiency Virus Type 1 Primary Isolates from Various Clades

  2002cites this paper
• Efficient Isolation of Novel Human Monoclonal Antibodies with Neutralizing Activity Against HIV-1 from Transgenic Mice Expressing Human Ig Loci1

  2002cites this paper
• Genetic engineering of Streptococcus gordonii for the simultaneous display of two heterologous proteins at the bacterial surface.

  2002cites this paper
• Herpesvirus saimiri-Immortalized Human Lymphocytes: Novel Hosts for Analyzing HIV Type 1 in Vitro Neutralization

  2002cites this paper
• The sequential introduction of HIV-1 subtype B and CRF01AE in Singapore by sexual transmission: accelerated V3 region evolution in a subpopulation of Asian CRF01 viruses.

  2002cites this paper
• Human monoclonal antibody stability and activity at vaginal pH.

  2002cites this paper
• Characterization of human monoclonal antibodies selected with a hypervariable loop-deleted recombinant HIV-1(IIIB) gp120.

  2001cites this paper
• Immunization with an interferon-gamma-gp120 fusion protein induces enhanced immune responses to human immunodeficiency virus gp120.

  2001cites this paper
• Conserved and Exposed Epitopes on Intact, Native, Primary Human Immunodeficiency Virus Type 1 Virions of Group M

  2000cites this paper
• Multi-envelope HIV vaccine safety and immunogenicity in small animals and chimpanzees

  2000cites this paper
• Effects of oligomerization on the epitopes of the human immunodeficiency virus type 1 envelope glycoproteins.

  2000cites this paper
• A Global Neutralization Resistance Phenotype of Human Immunodeficiency Virus Type 1 Is Determined by Distinct Mechanisms Mediating Enhanced Infectivity and Conformational Change of the Envelope Complex

  2000cites this paper
• A multi-mode chromatographic method for the comparison of the N-glycosylation of a recombinant HIV envelope glycoprotein (gp160s-MN/LAI) purified by two different processes.

  1999cites this paper
• Immunotyping of Human Immunodeficiency Virus Type 1 (HIV): an Approach to Immunologic Classification of HIV

  1999cites this paper
• Fine characterization of a V3-region neutralizing epitope in human immunodeficiency virus type 2.

  1999cites this paper
• The implications of antigenic diversity for vaccine development.

  1999cites this paper
• Exclusion of HIV Coreceptors CXCR4, CCR5, and CCR3 from the HIV Envelope

  1999cites this paper
• V3 serotyping of HIV-1 infection: correlation with genotyping and limitations.

  1999cites this paper
• Comparison of the Antibody Repertoire Generated in Healthy Volunteers following Immunization with a Monomeric Recombinant gp120 Construct Derived from a CCR5/CXCR4-Using Human Immunodeficiency Virus Type 1 Isolate with Sera from Naturally Infected Individuals

  1999cites this paper
• Dual specificity of a human neutralizing monoclonal antibody, specific for the V3 loop of GP120 (HIV-1).

  1999cites this paper